TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note published on Thursday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Price Performance

Shares of NASDAQ TXMD opened at $1.57 on Thursday. TherapeuticsMD has a twelve month low of $0.70 and a twelve month high of $2.75. The firm has a 50-day moving average of $1.33 and a two-hundred day moving average of $1.58.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.